{"id":"W2593423583","doi":"10.1016/s2352-3018(17)30031-0","title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","year":2017,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"ca_institutions":"Providence Health Care","funders":"Gilead Sciences","keywords":"Rilpivirine; Emtricitabine; Tenofovir alafenamide; Medicine; Regimen; Placebo; Cobicistat; Internal medicine; Tolerability; Clinical endpoint; Pharmacology; Randomized controlled trial; Human immunodeficiency virus (HIV); Virology; Adverse effect; Viral load; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001348839,0.001630418,0.002900876,0.0003982402,0.000349618,0.0009921115,0.0009037498,0.001655412,0.005185121],"category_scores_gemma":[0.0014499,0.000669502,0.001795978,0.0003874892,0.001207133,0.001248614,0.0003203609,0.002751399,0.0007924519],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007323369,"about_ca_system_score_gemma":0.000764107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001275405,"about_ca_topic_score_gemma":0.002207701,"domain_scores_codex":[0.9993601,0.0002813092,0.00004580258,0.0001224712,0.00004842623,0.0001419373],"domain_scores_gemma":[0.9992994,0.0002371671,0.0001357346,0.00006814609,0.00003544187,0.0002240499],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9659796,0.008398809,0.0004382927,0.0005047724,0.0008241566,0.00003493351,0.00008902958,0.0002836154,0.004383613,0.00008263775,0.000331941,0.01864868],"study_design_scores_gemma":[0.8865617,0.1098518,0.001895493,0.00002638453,0.0004071821,0.00002885255,0.00003177381,0.0002676551,0.0005145044,0.0001078878,0.0002890607,0.00001766396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951886,0.002026596,0.0003619207,0.0002050043,0.0002510565,0.0008833919,0.0003206982,0.00005094251,0.0007118136],"genre_scores_gemma":[0.9943095,0.001414486,0.0008733853,0.0004472491,0.0002266188,0.0009865678,0.0003405765,0.00001824588,0.001383306],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005185121,"threshold_uncertainty_score":0.01734596,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02301780583860628,"score_gpt":0.3063705951627395,"score_spread":0.2833527893241332,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}